Relevance of urocortins to cardiovascular disease

Emeto, Theophilus I.; Moxon, Joseph V.; Rush, Catherine M.; Woodward, Lynn; Golledge, Jonathan

doi:10.1016/j.yjmcc.2011.06.002

Cited by 26 publications

(19 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urocortins (UCN) are hormones members of the corticotropin-releasing hormone family that have an essential role in the central system and peripheral tissues [97]. In the last years, UCNs emerged as critical modulators of the cardiovascular system and relevant efforts have been engaged to explore its peripheral actions [97].…”

Section: Urocortinmentioning

confidence: 99%

“…In the last years, UCNs emerged as critical modulators of the cardiovascular system and relevant efforts have been engaged to explore its peripheral actions [97]. These endogenous hormones are peptides with 38 to 40 aminoacids that act through activation of two distinguished G-protein-coupled receptors (GPCR), corticotrophin-releasing factor receptor (CRFR) type 1 and type 2.…”

Section: Urocortinmentioning

confidence: 99%

“…CRFR1 and CRFR2 are expressed in the central system and periphery. However, the actions of CRFR2 predominate in the cardiovascular system [97,98].…”

Section: Urocortinmentioning

confidence: 99%

“…Various studies in humans and animals have shown the implication of UCNs in different cardiovascular disorders, such as atherosclerosis, myocardial infarct and heart failure [97,99,100]; however, its role on AAA has only been reported very recently [101,102]. The first evidence associating the UCNs to AAA was documented by Rush et al [102].…”

Section: Urocortinmentioning

confidence: 99%

See 3 more Smart Citations

Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture

Fraga‐Silva

Trachet²,

Stergiopulos³

2015

CPD

View full text Add to dashboard Cite

Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the management of cardiovascular diseases, there currently is no established drug therapy for AAA. Since the probability of death from a ruptured AAA still remains high, preventive elective repair of AAAs larger than 5.5 cm in luminal diameter is considered the best treatment option. However, perioperative complications are problematic as elective AAA repair comes with numerous intrinsic risks. Impelled by the need of improving AAA therapy, significant efforts have been made to identify pharmacological tools that would slow down AAA enlargement and lower the risk of rupture, thereby reducing the necessity of surgical intervention. In this review, we discuss recent findings addressing molecular targets that could potentially treat AAA, particularly addressing: statins, classical renin angiotensin system (RAS) blockers, the protective arm of RAS, renin inhibitors, tetracyclines, interleukin-1β inhibition, anti-angiogenic agents and urocortins.

show abstract

Section: Urocortinmentioning

confidence: 99%

Section: Urocortinmentioning

confidence: 99%

“…CRFR1 and CRFR2 are expressed in the central system and periphery. However, the actions of CRFR2 predominate in the cardiovascular system [97,98].…”

Section: Urocortinmentioning

confidence: 99%

Section: Urocortinmentioning

confidence: 99%

See 2 more Smart Citations

Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture

Fraga‐Silva

Trachet²,

Stergiopulos³

2015

CPD

View full text Add to dashboard Cite

show abstract

“…In particular, reports of improved cardiac output in heart failure patients treated with UCN2 and observed correlations of circulating UCN1 with cardiovascular disease severity confirm that the urocortins may be novel therapeutic, diagnostic and prognostic targets [discussed in detail in ref. 5]. …”

mentioning

confidence: 99%